Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.43 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.39 |
| ▸ | PDE1A | P54750 | 2/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19421605 | 0.92 | NTRK1 (0.47) | NTRK1PRMT6TYK2KMT2APDE1C | |
| SCHEMBL19429883 | 0.92 | NTRK1 (0.47) | NTRK1PRMT6TYK2KMT2AKDM5B | |
| SCHEMBL19430014 | 0.91 | PRMT6 (0.41) | NTRK1PRMT6PDE1CPDE1APDE1B | |
| SCHEMBL19430394 | 0.90 | PDE4B (0.48) | NTRK1PRMT6KMT2AKDM5BCHRM1 | |
| SCHEMBL17606388 | 0.90 | NTRK1 (0.46) | NTRK1PRMT6KMT2APDE1APDE1B | |
| SCHEMBL19429947 | 0.85 | PDE1B (0.44) | NTRK1PRMT6PDE1CPDE1APDE1B | |
| SCHEMBL19421613 | 0.84 | NTRK1 (0.47) | NTRK1PRMT6KMT2AKDM5BCHRM1 | |
| SCHEMBL19430101 | 0.83 | NTRK1 (0.45) | NTRK1PDE1APDE1BKDM5BPDE4B | |
| SCHEMBL19430243 | 0.82 | NTRK1 (0.42) | NTRK1PRMT6KMT2ACNR2MTOR | |
| SCHEMBL19421606 | 0.82 | NTRK1 (0.46) | NTRK1KMT2APDE1APDE1BKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | NTRK1 4670/4885PRMT6 4/4885TYK2 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.